There has been much progress in antiviral therapy for chronic hepatitis B; however, antiviral therapy for hepatitis B in special populations is still very challenging. Here, we review antiviral therapy for hepatitis B in special populations, including children and pregnant patients, patients with hepatitis-B-related cirrhosis, patients with acute hepatitis B and chronic hepatitis B surface antigen carriers who receive immunosuppressive or cytotoxic therapy. Major advances have been made in antiviral therapy for hepatitis B in these special populations because of recent increasing availability of oral nucleoside/nucleotide analogues that are well-tolerated and highly effective; however, the findings are mostly based on small uncontrolled short-term studies. More well-designed clinical studies on antiviral therapy for hepatitis B in these special populations are urgently needed to obtain more evidence-based high-quality data.
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There has been much progress in the treatment of chronic hepatitis B (CHB); however, treatment of hepatitis B in special populations remains very challenging [1] . These special populations include, but are not limited to, children, pregnant women, patients with hepatitis-B-related cirrhosis, patients with acute hepatitis B and chronic hepatitis B surface antigen (HBsAg) carriers receiving immunosuppressive or cytotoxic therapy. Most practice guidelines or consensus statements about hepatitis B management have mentioned antiviral therapy in these special populations, but the concrete principles and contents are variable and always in summary [2] [3] [4] . In this article, we reviewed antiviral therapy for hepatitis B in these special populations.
Children
Most children with chronic HBV infection are at the immunotolerant phase, demonstrated by positive serum hepatitis B e antigen (HBeAg) and high serum HBV DNA levels, but normal serum alanine aminotransferase (ALT) levels and liver biopsies that usually show mild or no necroinflammation. During this phase, the rate of spontaneous HBeAg loss is very low; however, no antiviral therapy is recommended because the efficacy of existing antiviral drugs is disappointing. For children with ALT levels ≥2× the upper limit of normal for >6 months and/or moderate or severe inflammation shown by liver biopsy, antiviral therapy should be considered. To date, only standard interferon (IFN)-α and lamivudine have been approved by the US Food and Drug Administration (FDA) to treat children.
The efficacy of IFN-α in children is similar to that in adult patients [5] . The recommended dose for patients aged 1-17 years is 6 MU/m 2 , to a maximum of 10 MU, three times per week. Children can tolerate IFN-α therapy relatively well; however, infants <1 year old should not receive IFN-α because of the risk of severe side effects, such as spastic diplegia [6] . Pegylated interferon (PEG -IFN) has not yet been approved by the FDA for children with CHB.
In a study of IFN-α2b therapy to treat children with HBeAg-positive CHB for 24 weeks, serum HBeAg and HBsAg became negative in 26% and 10% of 70 treated patients, respectively, compared with only 11% and 1% in 74 untreated controls. Serum ALT levels normalized and liver histology improved among responders [7] . However, the real effect of IFN-α therapy on the long-term course of HBV infection in children was challenged by the findings of several other studies [8] [9] [10] . In one study, a total of 107 children with HBeAg-positive CHB who received IFN-α for 3 or 6 months were followed-up and compared with 59 untreated controls. HBeAg loss occurred in 16 (15%) treated children during therapy and 18 (17%) during post-treatment follow-up; 31 (29%) Introduction non-responders lost HBeAg during subsequent years. After 5 years of observation, Kaplan-Meier estimates of cumulative HBeAg clearance rates were similar between treated (60%) and untreated control (65%) patients. HBsAg loss occurred in 4 (25%) patients who responded during treatment, but in none of the other treated or untreated patients. Thus, IFN-α might be particularly useful for patients who have more prominent disease activity and early response [9] .
Another study investigated the long-term outcome of 108 children with HBeAg-positive CHB. A total of 41 children were treated with IFN-α and 67 remained untreated [10] . After a median period of 12.1 years (range 5-23), HBeAg loss and HBV DNA clearance occurred in 80% of treated and 69.3% of untreated patients (P>0.05). In addition, HBsAg seroconversion rate was 9.7% in both treated and untreated patients. Therefore, IFN-α therapy could simply accelerate HBeAg seroconversion in some children, but its real effect on the overall long-term outcomes or natural history of the disease remain to be established.
Among the nucleoside/nucleotide analogues, only lamivudine has been approved by the FDA to treat children, and the recommended dose is 3 mg/kg/day with a maximum dose of 100 mg daily. Adefovir dipivoxil is also safe and efficient in children and adolescents aged 2-18 years at a dose of 0.25-0.3 mg/kg/day, with a maximal dose of 10 mg daily. Clinical trials are needed to study the safety and efficacy of other newer nucleoside/nucleotide analogues in children with CHB.
A randomized controlled study evaluated the efficacy and safety of lamivudine for HBeAg-positive children with serum ALT levels >1.3× the upper limit of normal but <500 IU/l for ≥3 months. The rate of virological response (HBeAg loss and negative HBV DNA) at week 52 was higher in 191 lamivudine-treated children than in 97 children who received a placebo (23% versus 13%; P=0.04). HBeAg seroconversion rates were 22% and 13% (P=0.06) in the lamivudine and placebo groups, respectively [11] . HBeAg seroconversion increased to 34% after 2 years of continuous treatment [12] , and HBeAg seroconversion was maintained in 82% and >90% of those who had received lamivudine for 1 year and ≥2 years, respectively. Treatment with lamivudine for up to 3 years was safe, and there was no obvious effect on weight or height growth [13] . However, the incidence of lamivudine-resistant HBV mutations increased with long-term therapy. Mutations in the YMDD region of the HBV polymerase gene, indicative of lamivudine resistance, developed in 19-24% of children after 1 year, in 49-59% after 2 years and in 64% after 3 years of lamivudine therapy. HBeAg seroconversion rates were lower in patients who had developed the YMDD mutation compared with those who had not [11] [12] [13] .
One study investigated the pharmacokinetic profile of adefovir dipivoxil in children and adolescents with CHB and found that the 0.3 mg/kg/day dose in children aged 2-6 years and the 10 mg daily dose in adolescents resulted in exposures comparable to those in adults given 10 mg daily. It was well-tolerated and no patient discontinued because of an adverse event related to the drug [14] .
In another study, a total of 173 children with HBeAgpositive CHB were randomized to receive adefovir dipivoxil or a placebo. At the end of 48 weeks, there were significantly more adefovir-dipivoxil-treated participants who reached the primary efficacy end point of serum HBV DNA<1,000 copies/ml and normal ALT, compared with placebo-treated participants (19.1% and 1.7%, respectively; P<0.001). The primary efficacy rates in children aged 12-17 years with adefovir dipivoxil and placebo treatment were 23% and 0%, respectively. HBeAg seroconversion rates at 48-weeks in adefovir-dipivoxil-treated children and placebotreated controls were 15.9% and 5.3%, respectively (P=0.051). No participant developed an adefovirdipivoxil-associated mutation that has been linked to HBV DNA rebound [15] .
To date, there have been no long-term studies on nucleoside/nucleotide analogues in children. It is probable that antiviral therapy with nucleoside/nucleotide analogues in children accelerate the spontaneous HBeAg seroconversion rates, as with IFN-α, and further longterm studies are needed to observe whether nucleoside/ nucleotide analogue treatment could improve the natural history of HBV infection in children.
Pregnancy
IFN-α or PEG-IFN-α have the advantage of a defined duration of therapy, with the aim of achieving sustained virological responses after treatment cessation, and could be the first-line choice for a young woman without pregnancy. During IFN-α therapy, the patient should be placed on contraception because IFN-α has the side effect of antiproliferation. If a woman on IFN-α therapy becomes pregnant or wants to become pregnant, IFN-α should be stopped or changed to oral nucleoside/nucleotide analogues.
Among the approved nucleoside/nucleotide analogues, telbivudine and tenofovir disoproxil fumarate are classified as category B by the FDA, whereas the other drugs, including lamivudine, adefovir dipivoxil and entecavir are classified as category C. To date, only the safety of lamivudine and tenofovir disoproxil fumarate during pregnancy has been supported by the cumulative Antiretroviral Pregnancy Registry data [16] . No overall increase in prevalence or any specific pattern of congenital anomalies has been detected with the use of lamivudine or tenofovir disoproxil fumarate, even when administered in the first trimester of pregnancy; however, there are insufficient numbers of pregnancy exposures to adefovir dipivoxil, entecavir and telbivudine to draw conclusions on exposure risk. When a patient becomes pregnant during antiviral therapy with nucleoside/nucleotide analogues, the risk of hepatitis flare or disease progression after the cessation of antiviral therapy and potential benefits for the patient if therapy is continued must be weighed against the potential mild risk to the fetus.
A second issue regarding antiviral therapy during pregnancy is related to the prevention of perinatal transmission of HBV, the main cause of chronic HBV infection in endemic areas. Despite adequate compliance to combined immunoprophylaxis with hepatitis B vaccination and hepatitis B immune globulin (HBIG), perinatal transmission of HBV still occurs in 5 -10% of infants born to HBsAg-positive mothers, which is significantly associated with maternal HBeAg positivity and high HBV DNA levels [17, 18] . Therefore, additional measures are urgently needed to protect infants born to highly viraemic mothers, and there have been several reports of antiviral therapy with lamivudine during the third trimester of pregnancy to prevent perinatal transmission of HBV. A study by van Nunen et al. [19] reported three highly viraemic pregnant women treated with 150 mg of lamivudine daily from week 36 of pregnancy until delivery. Their infants were HBV-DNA-negative at birth and remained negative, whereas all newborns of untreated women were HBV-DNA-positive.
In another study [20] , eight mothers with high HBV DNA levels (≥1.2×10 9 genome equivalents/ml) were treated with 150 mg of lamivudine daily during the final month of pregnancy. All newborns received hepatitis B vaccination and HBIG at birth, and were followed-up. Only 1 of 8 (12.5%) children born from these lamivudine-treated mothers was HBsAg-and HBV-DNA-positive at the age of 12 months, whereas perinatal transmission occurred in 7 of 25 (28%) children in the untreated historical control group.
In one randomized double-blind placebo-controlled study, 150 mothers with serum HBV DNA>1,000 meq/ ml were randomized to either 100 mg of lamivudine daily or placebo from week 32 of gestation to week 4 post-partum [21] . At delivery, mean ±sd HBV levels were 51.4 ±308.5 meq/ml in the lamivudine group compared with 2,168.8 ±1,646.0 meq/ml in the placebo group. HBV DNA levels in the lamivudine group remained suppressed throughout the treatment period. However, HBV DNA levels increased after treatment cessation at week 4 post-partum. HBV DNA levels were similar in the lamivudine and placebo groups at week 12 post-partum (3,035.8 ±3,200.4 meq/ml and 2,638.5 ±2,446.0 meq/ml, respectively). At birth, all infants received HBV vaccine with or without HBIG. At week 52 after birth, the primary analyses wherein missing data was counted as failures indicated that infants in the lamivudine plus vaccine plus HBIG group had a significantly lower incidence of HBsAg positivity ( compared with infants in the placebo plus vaccine plus HBIG group. Sensitivity analyses to evaluate the effect of missing data at week 52 resulting from a high dropout rate (13% in the lamivudine plus vaccine plus HBIG group and 31% in the placebo plus vaccine plus HBIG group) remained consistent with results of the primary analyses, such that lower transmission rates were still observed in the infants of lamivudine-treated mothers, but the differences were not statistically significant. No safety concerns were noted in the lamivudine-treated mothers or their infants.
There are still no convincing prospective controlled trials demonstrating the benefit of antiviral therapy in HBsAg-positive mothers to reduce the risk of perinatal transmission of HBV, particularly when prophylaxis with HBIG and HBV vaccination is provided to the newborns. Despite suppression of HBV DNA to undetectable levels in the mother by prolonged lamivudine therapy, the newborn could still develop chronic HBV infection [22] . The studies do indicate that lamivudine can be given safely during pregnancy. An important and still unresolved issue is whether this approach is safe for the mother, the major issues being post-treatment hepatitis flares and development of antiviral resistance [1] .
The safety of tenofovir disoproxil fumarate during pregnancy has also been supported by the cumulative Antiretroviral Pregnancy Registry data [16] . In some centres, tenofovir disoproxil fumarate has been used in this setting based on concerns of lower antiviral resistance and superior efficacy compared with lamivudine; however, further studies are needed to confirm the safety, efficacy or superiority of tenofovir disoproxil fumarate over lamivudine in highly viraemic mothers.
HBV-related cirrhosis
Longitudinal studies indicated that the annual incidence of cirrhosis was 2-10% in untreated patients with CHB and that the annual incidence of hepatic decompensation was 3.3-4.0% in patients with compensated HBV cirrhosis [23] [24] [25] . The prognosis was very poor once decompensated cirrhosis occurred: 1-year and 5-year survival rates were 55-70% and 14-28%, respectively [25] [26] [27] .
IFN-α is contraindicated in decompensated cirrhosis because of the significant side effects of severe bacterial infection and exacerbation of liver disease, even at low doses [28, 29] . Although it can be used in selective patients with advanced fibrosis or well-compensated cirrhosis, adverse events, such as fatigue, anorexia, thrombocytopaenia and hepatitis flares, occur more frequently. Careful monitoring is needed and the necessary dose reduction or premature discontinuation is more often during IFN-α therapy in patients with cirrhosis.
In a retrospective study of IFN-α in 200 patients with HBeAg-positive CHB, lower stage of fibrosis and higher grade of necroininflammation were identified as independent predictors of response to IFN-α. HBeAg seroconversion rate was significantly lower in patients with advanced fibrosis than in patients with minimal or no fibrosis [30] . However, the results of another study showed that PEG-IFN-α2b was at least as effective in patients with advanced fibrosis as in those without advanced fibrosis [31] . In that study, 70 patients with advanced fibrosis and 169 patients without, all with compensated liver disease, were treated with 52 weeks of PEG-IFN-α2b (100 µg weekly). Virological response, defined as HBeAg seroconversion and HBV DNA<10,000 copies/ml at week 78, occurred significantly more often in patients with advanced fibrosis than in those without (25% and 12%, respectively; P=0.02). Also, patients with cirrhosis exhibited a virological response more frequently than did patients without cirrhosis (30% and 14%, respectively; P=0.02). Improvement in liver fibrosis occurred more frequently in patients with advanced fibrosis (66% and 26%, respectively; P<0.001). HBsAg seroconversion rate was twice as high in patients with advanced fibrosis, although this difference was not statistically significant. Therefore, patients with CHB and advanced fibrosis or well-compensated cirrhosis should not be excluded from PEG-IFN treatment [31] . In the era of safe nucleoside/nucleotide analogues with low toxicity and a high barrier to resistance, however, nucleoside/nucleotide analogues have generally become first-line therapies for patients with both compensated and decompensated HBV cirrhosis [32] .
A large controlled clinical trial confirmed that continuous treatment with lamivudine could delay clinical progression in patients with CHB and advanced fibrosis or cirrhosis [33] . In that study, 651 patients with CHB and histologically confirmed cirrhosis or advanced fibrosis were treated with lamivudine or placebo for a median duration of 32.4 months. End points defined as hepatic decompensation, hepatocellular carcinoma, spontaneous bacterial peritonitis, bleeding gastroesophageal varices, or death related to liver disease were reached by 7.8% in the lamivudine group and 17.7% in the placebo group (P=0.001). The Child-Pugh score increased in 3.4% of the patients receiving lamivudine and 8.8% of those receiving placebo (P=0.02), whereas hepatocellular carcinoma occurred in 3.9% of those in the lamivudine group and 7.4% of those in the placebo group (P=0.047). Overall, 12% of patients in the lamivudine group and 18% of patients in the placebo group reported serious adverse events. Genotypic resistant YMDD mutations developed in 49% of the patients treated with lamivudine, and the Child-Pugh score was more likely to increase in patients with these mutations than in the other patients treated with lamivudine (7% and <1%, respectively).
Antiviral therapy with lamivudine is therefore safe and efficient for patients with CHB and advanced fibrosis or cirrhosis; however, the possibility of lamivudineresistant mutations should be cautioned with long-term therapy. One study showed that the rate of hepatic decompensation after viral breakthrough because of lamivudine-resistant mutations was much higher in patients with cirrhosis than those without cirrhosis (23% and 4%, respectively; P=0.001) [34] .
Entecavir is also safe and efficient to treat patients with CHB and advanced fibrosis or compensated cirrhosis, as shown by the results of three large randomized multicentre Phase III studies [35] . Two trials enrolled nucleoside/nucleotide-analogue-naive patients randomized to ≥48 weeks of entecavir 0.5 mg/day or lamivudine 100 mg/day. The third trial randomized lamivudine-refractory patients to 48 weeks of entecavir 1 mg/day or lamivudine 100 mg/day. Of the 1,633 treated patients, 245 had advanced liver fibrosis/cirrhosis (Ishak fibrosis stages 4-6). Among patients with advanced liver fibrosis, improvement in Ishak fibrosis score was observed in 57% of nucleoside/nucleotideanalogue-naive HBeAg-positive patients, 59% of nucleoside/nucleotide-analogue-naive HBeAg-negative patients and 43% of lamivudine-refractory HBeAgpositive patients following entecavir therapy, versus 49%, 53% and 33% of lamivudine-treated patients. The overall trends in other histological, virological, biochemical and serological outcomes in entecavir-treated patients with advanced liver fibrosis/cirrhosis were consistent with those observed in the overall study populations in each trial. The treatment was well-tolerated.
The evidence about the safety and efficacy of nucleoside/nucleotide analogues to treat decompensated HBV cirrhosis is mostly from clinical trials with lamivudine [36] [37] [38] [39] [40] . Hepatic impairment does not warrant dose modification of lamivudine because there are no statistical differences in overall lamivudine exposure or other major pharmacokinetic parameters between healthy control participants and patients with moderate or severe hepatic impairment [41] . In a multicentre study, 77 HBsAg-positive liver transplant candidates undergoing lamivudine therapy appeared to have improved survival, and transplanted patients had a decreased rate of recurrent HBV infection when compared with historical cohorts [39] . The results of another study also supported the efficacy of lamivudine in patients with decompensated HBV cirrhosis [40] . The Child-Pugh score and the survival was markedly improved, the need for liver transplantation was decreased, and time to death or liver transplantation was significantly longer in 23 lamivudine-treated patients than in controls.
Selection of lamivudine-resistant mutants is the main concern with long-term lamivudine therapy. In one study of long-term lamivudine monotherapy for patients with decompensated HBV cirrhosis, liver-related death occurred in five of eight patients soon after the development of biochemical breakthrough caused by YMDD mutants [42] . However, if recognized early and salvage therapy promptly initiated, the development of lamivudine-resistant mutations did not impair the patients' clinical outcome, as shown by the findings in the National Institutes of Health HBV orthotopic liver transplantation study [43] . In that study, after a median time of 40.5 months with lamivudine therapy, 44 (36.1%) patients developed antiviral failure (either virological breakthrough, defined as an increase in serum HBV DNA by >1 log 10 copies/ml from nadir or genotypical resistance defined as detection of YMDD mutation). Among 42 patients who started salvage therapy with adefovir dipivoxil after a median of 5 months, 21 (50%) patients had a full response and 11 (26.2%) patients had a suboptimal virological response, but remained clinically compensated. Antiviral failure was not a significant predictor of transplant or death if patients were provided with timely salvage therapy.
One study evaluated the efficacy and safety of the addition of adefovir dipivoxil to lamivudine for 52 weeks in 40 patients with decompensated hepatitis B or post-liver transplantation and YMDD mutant HBV, and found that 92% (36/39) of patients had an HBV DNA response (median change of -4.6 log 10 copies/ml) and improved liver chemistries (P<0.001). The regimen was well-tolerated and renal function abnormalities were not observed [44] .
In another study, 226 liver transplantation wait-listed patients with lamivudine-resistant HBV were treated with adefovir dipivoxil. Serum HBV DNA levels became undetectable (<1,000 copies/ml) in 59% and 65% of patients at weeks 48 and 96, respectively [45] . After 48 weeks, ALT, albumin, bilirubin and prothrombin time normalized in 77%, 76%, 60% and 84% of patients, respectively. Kaplan-Meier estimates of survival were 86% by week 48 and 78% by week 96. Some patients were able to be removed from the wait-list as a result of clinical improvement. Adefovir dipivoxil was generally well-tolerated and there were only 11 patients (6%) who had confirmed increases of serum creatinine concentrations of ≥0.5 mg/dl from baseline during the course of the study. Therefore, adefovir dipivoxil is efficient to treat lamivudine resistant HBV, and the combination therapy with lamivudine and adefovir dipivoxil is better than switching to adefovir dipivoxil monotherapy, which could decrease the risk of ALT flare and the future emergence of adefovir dipivoxil resistance [46] [47] [48] [49] .
One study evaluated the efficacy of entecavir 0.5 mg daily in 70 treatment-naive patients with decompensated HBV cirrhosis [50] . Among 55 patients being treated for ≥12 months, the cumulative transplantation-free survival was 87.1% at 1 year. Child-TurcottePugh and model for end-stage liver disease (MELD) scores were improved. The 1-year cumulative rates of HBV DNA negativity and HBeAg loss were 92.3% and 54.0%, respectively, by intention-to-treat analysis. The rates of HBV DNA negativity, HBeAg seroconversion/ loss and ALT normalization at month 12 were similar for the decompensated and compensated groups.
Tenofovir disoproxil fumarate has superior antiviral efficacy with a similar safety profile compared with adefovir dipivoxil [51] . One study has shown that tenofovir disoproxil fumarate alone or combined with lamivudine could exert greater viral reduction than adefovir dipivoxil for lamivudine-resistant HBV [52] , and is also a highly effective rescue drug for patients with lamivudine-resistant HBV infection and incomplete virological response to adefovir dipivoxil [53] . Therefore, lamivudine is safe and efficient in patients with decompensated HBV cirrhosis. Other newer nucleoside/ nucleotide analogues, such as entecavir and tenofovir disoproxil fumarate, that are more potent and with much lower resistance rates, should be more feasible to treat decompensated HBV cirrhosis. Otherwise, combination therapy with lamivudine or telbivudine and adefovir dipivoxil could be chosen. One randomized double-blind study showed that lamivudine and adefovir dipivoxil combination therapy for 2 years was more efficient to reach lower rates of lamivudine resistance, lower serum HBV DNA levels and higher rates of ALT normalization than lamivudine monotherapy in treatment-naive patients with HBeAg-positive CHB [54] .
Antiviral therapy with nucleoside/nucleotide analogues can rapidly inhibit HBV replication in decompensated HBV cirrhosis; however, clinical efficacy is not obvious until 3-6 months later. Thus, antiviral therapy should be started promptly in decompensated HBV cirrhotic patients to postpone or avoid the need of liver transplantation, without an emphasis on high HBV DNA or increased ALT levels [55] . The duration of antiviral therapy should be lifelong to avoid mortal hepatitis flares after stopping antiviral therapy, even if the patient's condition has been obviously improved.
During antiviral therapy, careful monitoring for patient compliance, viral resistance and hepatitis flares, as well as ongoing surveillance of hepatocellular carcinoma, is still necessary because the risk, although thought to be reduced by therapy, it is not eliminated. In addition, patients should be registered to a liver transplant centre to determine whether they require liver transplantation. Another important consideration is the risk of lactic acidosis in patients with cirrhosis during entecavir treatment. In one report [56] , 5 of 16 patients with cirrhosis developed lactic acidosis between 4 and 240 days after treatment initiation with entecavir. All patients who developed lactic acidosis had MELD scores ≥20 and no increased lactate serum concentrations were observed in the other 11 patients with MELD scores <18. Lactic acidosis was lethal in one patient but resolved in the other cases after termination/interruption of entecavir treatment. Therefore, caution must be exercised when using entecavir in patients with advanced liver cirrhosis.
Acute hepatitis B
More than 95% of immunocompetent patients with acute hepatitis B could recover spontaneously within 6 months, deeming antiviral therapy unnecessary. However, for patients with acute hepatitis B who have markedly prolonged prothrombin time and deep jaundice persisting for >4 weeks, antiviral therapy with nucleoside/nucleotide analogues should be considered, and continuation for ≥3 months after seroconversion to antibody against HBsAg (anti-HBs) or ≥6 months after HBeAg seroconversion without HBsAg loss is recommended [3] . Lamivudine and telbivudine could be the first-line option and entecavir can also be used, but tenofovir disoproxil fumarate might not be optimal because of its potential for nephrotoxicity. Adefovir dipivoxil is not suitable as a first choice because its efficacy to inhibit HBV replication is relatively slow and it has the potential for nephrotoxicity [2] . IFN-α is contraindicated for such patients because it could aggravate hepatitis flare. Sometimes, it is very difficult to differentiate true acute hepatitis B and reactivation of CHB without liver biopsy. However, antiviral therapy with nucleoside/nucleotide analogues is suitable in both conditions. Several uncontrolled studies have shown that lamivudine could inhibit HBV replication promptly, and improve liver function tests and survival in patients with severe acute hepatitis B [57] [58] [59] [60] . However, the results of a randomized controlled study showed that lamivudine therapy for 3 months in 31 patients with severe acute hepatitis did not significantly improve biochemical or clinical outcomes compared with 40 patients receiving placebo. Although at week 4, HBV DNA levels were significantly lower in the lamivudine group than in the control group, HBV DNA levels were comparable in the two groups thereafter [61] .
Immunosuppressive or cytotoxic therapy
HBV reactivation could occur in 20-50% of HBsAgpositive patients undergoing immunosuppressive or cytotoxic therapy, and is mostly seen in patients with high baseline HBV DNA levels and/or who receive large doses of glucocorticoids or marcellomycin [62, 63] . Patients with rheumatic diseases or inflammatory bowel diseases who receive anti-tumour necrosis factor-α therapy are also at risk of HBV reactivation [64, 65] . Most patients with HBV reactivation are asymptotic; however, jaundice, and even fatal liver failure, might occur in a few patients. Preventive therapy with nucleoside/nucleotide analogues is safe and efficient to decrease the risk of HBV reactivation, whereas IFN-α is not suitable because of its side effects, including marrow suppression and possible induction of hepatitis flares. One exception is among HBsAg-negative but hepatitis B core antibody (antiHBc)-positive patients who receive chemotherapy containing rituximab (a chimeric mouse human monoclonal antibody against CD20 + malignant lymphoid cells), for whom the risk of HBV reactivation is high [66] [67] [68] [69] . Therefore, these anti-HBc-positive patients should also receive preventive antiviral therapy before the initiation of rituximab.
Several studies have shown that preventive therapy with lamivudine could decrease the risk of HBV reactivation in HBsAg-positive patients undergoing immunosuppressive or cytotoxic drugs, and ensure successful accomplishment of immunosuppressive or cytotoxic therapy [70, 71] .
A systematic review including 14 studies (2 randomized controlled trials, 8 prospective cohort studies and 4 retrospective cohort studies) found that preventive therapy with lamivudine for HBsAg-positive patients undergoing chemotherapy might reduce the risk of HBV reactivation and HBV-associated morbidity and mortality [72] . There were 275 patients in the preventive lamivudine group and 475 control participants evaluated for the primary end point of HBV reactivation. With preventive lamivudine therapy, the relative risk for both HBV reactivation and HBV-related hepatitis ranged from 0.00-0.21. No patients developed HBVrelated hepatic failure (0 of 108 patients in the lamivudine group versus 21 of 162 control patients), and only 4 deaths were attributable to HBV in the preventive lamivudine group (4 of 208 patients versus 27 of 394 control patients). Lamivudine was well-tolerated, and no adverse effects were noted.
Other newer nucleoside/nucleotide analogues might also be suitable as preventive therapy, and more clinical trials are needed to confirm their safety and efficacy among patients undergoing immunosuppressive or cytotoxic treatment. If the expecting course of preventive antiviral therapy is short (<12 months), lamivudine or telbivudine could be used. If the expecting course is >12 months, nucleoside/nucleotide analogues with low resistance risk, such as adefovir dipivoxil, entecavir or tenofovir disoproxil fumarate, should be chosen [2] ; entecavir and tenofovir disoproxil fumarate are more suitable because both can inhibit HBV replication more rapidly than adefovir dipivoxil.
For patients who are negative for HBsAg, but positive for anti-HBc or concomitantly positive for antiHBs, the risk of HBV reactivation during or after immunosuppressive therapy, unless with rituximab, is very low, and there are not yet enough clinical trials to support the routine use of preventive antiviral therapy. However, close monitoring of the patients' serum HBV DNA and ALT levels is necessary to detect possible HBV reactivation in time. Antiviral therapy with nucleoside/nucleotide analogues should begin promptly when HBV DNA is detectable, ideally before ALT flares.
Summary
There has been much progress in antiviral therapy for CHB in special populations because of recent increasing availability of oral nucleoside/nucleotide analogues that are well-tolerated and highly effective; however, most of the findings a re based on small, uncontrolled and short-term studies of lamivudine. Newer nucleoside/nucleotide analogues, such as entecavir and tenofovir disoproxil fumarate, are more potent than lamivudine to inhibit HBV replication and have much lower resistance rates, but clinical studies about their safety and efficacy in these special populations are still very rare. Therefore, more well-designed clinical studies on antiviral therapy for hepatitis B in these special populations are urgently needed to establish more evidence-based high-quality data.
